MedTrace Logo

Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy

NCT00419653 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2008-09-16

No results posted yet for this study

Summary

The study aims to investigate the modulation of regional brain activation in schizophrenic patients by psychopharmacological treatment with either haloperidol, amisulpride or olanzapine. The study will be performed with functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI).

Conditions

Interventions

DRUG

Amisulpride

DRUG

Olanzapine

DRUG

Haloperidol

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • University of Jena

    lead OTHER

Principal Investigators

  • Ralf Schlösser, M.D. · FSU Jena

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2007-09-30
Completion
2007-09-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00419653 on ClinicalTrials.gov